Literature DB >> 6199140

Hepatitis B surface antigen containing immune complexes occur in seronegative hepatocellular carcinoma patients.

S E Brown, C R Howard, M W Steward, A B Ajdukiewicz, H C Whittle.   

Abstract

IgG, IgM and hepatitis B surface antigen (HBsAg) containing immune complexes (IC) were detected by the Clq and conglutinin solid phase assays in both HBsAg+ and HBsAg- groups of patients with primary hepatocellular carcinoma (HCC). No differences were observed between the two patient groups either in the levels of antigen non-specific and HBsAg specific complexes or in the immunoglobulin isotype in the complexes. The results show that HBsAg can occur in an IC form in the sera of patients classified as HBsAg- by sensitive commercial assays and provides evidence of a further association of hepatitis B virus (HBV) and HCC in antigen negative patients. Furthermore, the HBsAg IC in HCC patients differ from those in other HBV infected subjects in that they are preferentially detected by the Clq assay.

Entities:  

Mesh:

Substances:

Year:  1984        PMID: 6199140      PMCID: PMC1535819     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  16 in total

Review 1.  Hepatocellular carcinoma and the hepatitis B virus: evidence for a causal association.

Authors:  W Szmuness
Journal:  Prog Med Virol       Date:  1978

Review 2.  Isolation of immune complexes and characterisation of their constituent antigens and antibodies in some human diseases: a review.

Authors:  V E Jones; E Orlans
Journal:  J Immunol Methods       Date:  1981       Impact factor: 2.303

3.  Hepatitis B infection and primary liver cancer.

Authors:  P Maupas; J L Melnick
Journal:  Prog Med Virol       Date:  1981

4.  Hepatitis B virus infection and primary hepatocellular carcinoma.

Authors:  E Tabor; R J Gerety; C L Vogel; A C Bayley; P P Anthony; C H Chan; L F Barker
Journal:  J Natl Cancer Inst       Date:  1977-05       Impact factor: 13.506

5.  Antibody to hepatitis B core antigen in patients with hepatocellular carcinoma.

Authors:  Y Kubo; K Okuda; M Hashimoto; Y Nagasaki; H Ebata
Journal:  Gastroenterology       Date:  1977-06       Impact factor: 22.682

6.  Measurement of antigen-antibody complexes in mouse sera by conglutinin, C1q and rheumatoid factor solid phase binding assays.

Authors:  M E Devey; J Taylor; M W Steward
Journal:  J Immunol Methods       Date:  1980       Impact factor: 2.303

7.  Hepatitis B virus infection in two Gambian villages.

Authors:  H C Whittle; A K Bradley; K McLauchlan; A B Ajdukiewicz; C R Howard; A J Zuckerman; I A McGregor
Journal:  Lancet       Date:  1983-05-28       Impact factor: 79.321

8.  Chronic liver disease: the detection and characterization of circulating immune complexes.

Authors:  S E Brown; M W Steward; L Viola; C R Howard; I M Murray-Lyon
Journal:  Immunology       Date:  1983-08       Impact factor: 7.397

9.  State of hepatitis B virus DNA in hepatocytes of patients with hepatitis B surface antigen-positive and -negative liver diseases.

Authors:  C Bréchot; M Hadchouel; J Scotto; M Fonck; F Potet; G N Vyas; P Tiollais
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

10.  Hepatitis B vaccine: demonstration of efficacy in a controlled clinical trial in a high-risk population in the United States.

Authors:  W Szmuness; C E Stevens; E J Harley; E A Zang; W R Oleszko; D C William; R Sadovsky; J M Morrison; A Kellner
Journal:  N Engl J Med       Date:  1980-10-09       Impact factor: 91.245

View more
  5 in total

1.  Relationship of serum alpha-fetoprotein to circulating immune complexes and complements in patients with hepatitis B surface antigen-positive hepatocellular carcinoma.

Authors:  J F Tsai; J H Tsai; W Y Chang
Journal:  Gastroenterol Jpn       Date:  1990-06

Review 2.  Molecular mechanisms underlying occult hepatitis B virus infection.

Authors:  Jasmine Samal; Manish Kandpal; Perumal Vivekanandan
Journal:  Clin Microbiol Rev       Date:  2012-01       Impact factor: 26.132

3.  Hepatitis C virus associated primary hepatocellular carcinoma in a noncirrhotic liver.

Authors:  W Herr; G Gerken; T Poralla; S Immenschuh; P Schirmacher; K W Steegmüller; H Schwickert; K H Meyer zum Büschenfelde
Journal:  Clin Investig       Date:  1993-01

Review 4.  "Complimenting the Complement": Mechanistic Insights and Opportunities for Therapeutics in Hepatocellular Carcinoma.

Authors:  Astha Malik; Unmesha Thanekar; Surya Amarachintha; Reena Mourya; Shreya Nalluri; Alexander Bondoc; Pranavkumar Shivakumar
Journal:  Front Oncol       Date:  2021-02-24       Impact factor: 5.738

5.  Hepatitis B, C and D virus infections and risk of hepatocellular carcinoma in Africa: A meta-analysis including sensitivity analyses for studies comparable for confounders.

Authors:  Donatien Serge Mbaga; Sebastien Kenmoe; Cyprien Kengne-Ndé; Jean Thierry Ebogo-Belobo; Gadji Mahamat; Joseph Rodrigue Foe-Essomba; Marie Amougou-Atsama; Serges Tchatchouang; Inès Nyebe; Alfloditte Flore Feudjio; Ginette Irma Kame-Ngasse; Jeannette Nina Magoudjou-Pekam; Lorraine K M Fokou; Dowbiss Meta-Djomsi; Martin Maïdadi-Foudi; Sabine Aimee Touangnou-Chamda; Audrey Gaelle Daha-Tchoffo; Abdel Aziz Selly-Ngaloumo; Rachel Audrey Nayang-Mundo; Jacqueline Félicité Yéngué; Jean Bosco Taya-Fokou; Raoul Kenfack-Momo; Efietngab Atembeh Noura; Cynthia Paola Demeni Emoh; Hervé Raoul Tazokong; Arnol Bowo-Ngandji; Carole Stéphanie Sake; Etienne Atenguena Okobalemba; Jacky Njiki Bikoi; Richard Njouom; Sara Honorine Riwom Essama
Journal:  PLoS One       Date:  2022-01-21       Impact factor: 3.752

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.